OriGene Technologies has raised $16m to build what is described as the largest collection of next-generation monoclonal antibodies, which will cover the majority of the human proteome.

The funding will be used to continue to build OriGene’s TrueMAB monoclonal antibody collection, which will use authentic human full-length proteins as immunogens during the manufacturing process.

OriGene chairman and chief executive officer Wei-Wu He said that the funding will propel the company closer to meeting its goal of building the largest monoclonal antibody collection in the world.

“The collection will cover the entire human genome of approximately 20,000 genes,” He said.

OriGene has dedicated the last decade to building the largest collection of human full-length cDNA clones in the world, which has enabled OriGene to manufacture human full-length proteins directly from human cells for producing monoclonal antibodies.

According to the company, TrueMAB monoclonal antibodies generated by authentic human antigen have been proven far superior to traditional small peptide-generated monoclonal and polyclonal antibodies, especially in applications such as flow cytomery and multiplex ELISA assays.

The $16m Series B financing was raised from a group led by IDG-Accel, SBI & TH Venture Capital Enterprise and Zero2IPO.